Ampio Pharmaceuticals, Inc. (AMPE): BCG Matrix [Dec-2025 Updated]

You're looking at the final chapter for Ampio Pharmaceuticals, Inc., and frankly, the Boston Consulting Group Matrix tells a grim story of assets in liquidation rather than growth. Since the corporate entity began dissolving in August 2024, we aren't looking for Stars or Cash Cows; instead, the entire operation has collapsed into the 'Dog' quadrant, with a stock price hovering near $0.0052 as of November 2025. The only remaining question is how the final cash from asset sales, after settling liabilities like the $3 million settlement, will-or won't-reach shareholders. Dive in to see the stark reality of this wind-down through the four classic lenses.

Background of Ampio Pharmaceuticals, Inc. (AMPE)

You're looking at Ampio Pharmaceuticals, Inc. (AMPE), a company that, since its founding in 2008, has been focused on developing therapeutic solutions for various inflammatory conditions. Honestly, this is a classic small-cap biotech story, centered on leveraging proprietary science. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado, and operates in the development space, aiming to bring new drugs to market. The firm's strategy has long involved exploring new uses for already approved drugs alongside developing entirely new molecular entities (NMEs) to cut down on development timelines and risk, though that strategy has faced headwinds recently.

The main event for Ampio Pharmaceuticals, Inc. has been its OA-201 program, a small molecule formulation intended to treat pain and potentially preserve cartilage in osteoarthritis of the knee (OAK). However, you should know that the path forward got significantly rockier in early 2024. Ampio Pharmaceuticals, Inc. announced that efficacy results from late-stage preclinical studies for OA-201 did not support the Investigational New Drug (IND) submission they were hoping to file in early 2025. That news definitely shifted the focus for the organization.

Beyond OA-201, the pipeline included other interesting, albeit less central, candidates. For instance, they were looking at an inhalation form of a biologic drug, AMP5A, which had been studied in Phase I trials for respiratory complications due to COVID-19, showing some promising early signals on mortality reduction. To manage resources after the OA-201 setback, the company, under President and CEO Mark A. Biancamano, announced a voluntary delisting and SEC deregistration back in March 2024. They were also actively streamlining operations, aiming to save approximately $4.6 million annually by reducing staff and subleasing facilities.

Financially speaking, Ampio Pharmaceuticals, Inc. remains firmly in the pre-revenue stage. As of the end of 2023, the trailing 12-month revenue was reported as $0, and the company posted earnings (Pretax Income) of -$8.63 million for the TTM ending December 30, 2023. Looking at the very end of 2025, market data suggests a very low market capitalization, reported around $5.9K, and a stock price hovering near $0.02080 per share, reflecting the high-risk, development-stage nature of the business.

Ampio Pharmaceuticals, Inc. (AMPE) - BCG Matrix: Stars

Honestly, you won't find any Stars here; this category requires high market growth and high market share, which is impossible for a dissolved, pre-revenue company.

When we look at the Boston Consulting Group (BCG) framework, a Star needs robust market share in a rapidly expanding market. For Ampio Pharmaceuticals, Inc., that analysis is moot because the operational entity is winding down. You're looking at a company that has already executed its exit strategy, not one building a future cash cow.

Here's the quick math on the current corporate status, which dictates this quadrant's emptiness:

• - No commercial products exist to capture high market share in any high-growth therapeutic area.
• - The company's corporate entity is in the process of dissolution as of August 16, 2024.
• - All primary drug candidates have either been discontinued or failed to advance to commercial stages.

To be fair, the company's last reported financial context showed a lack of operating revenue and significant accumulated deficit as of September 30, 2023, which was $240.5 million. This pre-dissolution financial reality confirms the absence of any product capable of achieving the high market share required for a Star classification. Furthermore, as of November 18, 2025, the common stock was trading at approximately $0.005200 USD on OTC Markets, reflecting its status post-dissolution. The focus now is on the distribution of residual cash, not product investment.

The key takeaway here is that the strategic investment required for a Star-the very definition of this BCG quadrant-is no longer applicable. Any remaining value hinges on the successful settlement of legal obligations and subsequent court approval for distribution to stockholders, a process entirely separate from product commercialization.

Ampio Pharmaceuticals, Inc. (AMPE) - BCG Matrix: Cash Cows

A Cash Cow is a mature product that generates reliable cash flow; Ampio Pharmaceuticals, Inc. has none, as it is a development-stage firm that never reached commercialization.

• - Ampio Pharmaceuticals is a pre-revenue stage biopharmaceutical company with no approved products for sale.
• - The primary product candidate, Ampion, was discontinued after a lack of efficacy in a key trial.
• - The company's annual revenue was negligible, reported at $76.8K as far back as 2014, with no significant revenue since.
• - The company's focus is on liquidating assets, not managing a profitable product portfolio.

You see, for a product to be a Cash Cow, it needs a high market share in a mature market, meaning it's printing money reliably. Ampio Pharmaceuticals, Inc. simply hasn't gotten there; in fact, they've stopped the main development program.

The reality for Ampio Pharmaceuticals, Inc. as of the latest filings, which informs our 2025 strategic view, is a complete absence of commercial product revenue, which is the bedrock of any Cash Cow. The focus has shifted entirely to managing limited capital while assessing strategic alternatives, which is the opposite of milking a mature product line.

The firm's operational structure reflects this lack of a cash-generating core. With only 12 employees as of the latest profile data, the overhead is minimal, but so is the revenue-generating capacity. The market capitalization as of March 15, 2024, was only $1.85M, trading at a price of $1.63 per share, which shows the market values the company based on its pipeline potential (AR-300) and asset base, not on established product sales.

• - Discontinued development of Ampion for Osteoarthritis and COVID-19.
• - Withdrew 3 Investigational New Drug (IND) applications.
• - Current focus on preclinical development of AR-300.
• - As of December 31, 2022, cash and cash equivalents were $12.7 million.
• - Lease payments for headquarters/labs were approximately $30,000 monthly, with a sublease in place until September 2024.

Honestly, you're looking at a company in a holding pattern, not one managing a steady stream of profits. Any capital raised now is for the next speculative bet, AR-300, not for maintaining a Cash Cow.

Ampio Pharmaceuticals, Inc. (AMPE) - BCG Matrix: Dogs

This is where the entire business lands, unfortunately-low market share and low market growth, which is the definition of a company in dissolution. For Ampio Pharmaceuticals, Inc., the entire corporate entity functions as the Dog in the matrix, given the lack of viable products and the decision to cease public reporting.

You're looking at a situation where the market has already priced in the terminal value, which is why the numbers look the way they do. Honestly, when a company voluntarily exits the public reporting structure, it's signaling that the cost of compliance outweighs any perceived benefit of public trading, which is a classic Dog move to conserve the remaining cash.

• The corporate entity itself is a Dog, having voluntarily announced delisting from the NYSE American and intent to deregister from the SEC on March 25, 2024.
• The stock price was approximately $0.0052 as of November 25, 2025, reflecting near-zero market confidence and value.
• The OA-201 program, the last development opportunity, failed to support an Investigational New Drug (IND) submission following efficacy results announced on February 14, 2024.
• The company's market capitalization was approximately $5.9K as of November 26, 2025, a clear indicator of a Dog.

Here's the quick math on the key metrics defining this Dog status as of late 2025. This data shows a near-total evaporation of enterprise value, which is what happens when the growth engine stalls and the market share is effectively zero.

Dogs are units or products with a low market share and low growth rates. They frequently break even, neither earning nor consuming much cash. Dogs are generally considered cash traps because businesses have money tied up in them, even though they bring back almost nothing in return. These business units are prime candidates for divestiture. For Ampio Pharmaceuticals, Inc., the entire operation fits this profile; expensive turn-around plans usually do not help when the core asset-the pipeline-has been exhausted, so management is focused on preserving cash during an orderly wind down.

Ampio Pharmaceuticals, Inc. (AMPE) - BCG Matrix: Question Marks

You're looking at a business unit-or in this case, a corporate wind-down-that is consuming cash while the final outcome remains highly speculative. The only remaining Question Mark for Ampio Pharmaceuticals, Inc. is the uncertain outcome of the wind-down process, which requires cash to settle liabilities before any potential return to shareholders. Honestly, these situations are tough because the cash burn is real, but the potential upside is tied up in legal finality.

These units, which in a normal company would be new products in growing markets but with low market share, are essentially consuming capital now. For Ampio Pharmaceuticals, Inc., this consumption is driven by necessary final obligations. These elements have high demands for cash and, due to the lack of a continuing core business, bring little in return right now. They lose the company money, but since the market-shareholders-are waiting for a final distribution, the hope is that the remaining assets, after settling debts, could turn into a positive return, though that potential is low.

The best way to handle these Question Marks is to resolve the liabilities quickly or sell off the remaining assets, but here, the resolution is dictated by legal processes. We need to see how much cash is left after these required payments are made. Here's the quick math on the most significant known liability that must be settled first:

The uncertainty here is massive, and it's all about timing and court approval. If onboarding takes 14+ days, the final cash distribution timeline gets pushed, which is a risk for shareholders waiting for any recovery.

• The primary Question Mark is the potential for a cash distribution to stockholders post-dissolution.
• The availability and timing of any cash distribution are uncertain and subject to approval by the Delaware Chancery Court.
• Ongoing legal liabilities, including a $3 million settlement for a securities fraud class action, consume remaining capital.
• The company received an audit opinion with a going concern explanation in April 2024, highlighting significant financial uncertainty.

To be fair, the finalization of the securities fraud class action settlement, which received final approval in February 2025, was a major step in clearing one of the known drains on capital. Still, the ultimate value remaining for shareholders depends on what's left after all administrative and legal costs are paid from that fund, plus any other outstanding obligations. Finance: draft 13-week cash view by Friday, focusing on post-settlement cash balances.